Verrica Pharmaceuticals (NASDAQ: VRCA) — Company Overview, News & Financial Data
Verrica Pharmaceuticals develops innovative dermatological treatments, focusing on molluscum contagiosum and skin diseases.
Verrica Pharmaceuticals
Verrica Pharmaceuticals (NASDAQ:VRCA) is a dermatology-focused company dedicated to developing and commercializing innovative treatments for skin diseases. Their flagship project involves a topical therapy designed to address molluscum contagiosum, a viral infection causing skin lesions. With this effort, Verrica aims to meet the pressing needs of patients who suffer from this and other underserved medical conditions. Their commitment extends beyond molluscum contagiosum, as they leverage their proprietary technology to explore treatments for additional dermatological issues. The company's ultimate objective is to improve the lives of those afflicted by challenging skin diseases through the power of science and innovation.
Snapshot
Operations
Products and/or services of Verrica Pharmaceuticals
- VP-102 for the treatment of molluscum contagiosum, a highly contagious skin infection.
- VP-103 for plantar warts, leveraging the company’s proprietary cantharidin formulation.
- VP-102 for common warts, expanding the applications of their lead compound.
- Research on cantharidin-based formulations for potential use in other dermatological conditions.
- Partnership initiatives for the commercialization and distribution of their dermatological treatments.
- Development of a pipeline focusing on unmet needs in pediatric dermatology.
Verrica Pharmaceuticals executive team
- Jayson M. RiegerPresident, CEO & Director
- John J. KirbyInterim Chief Financial Officer
- Noah L. RosenbergChief Medical Officer
- David ZawitzCOO, Chief Legal Officer & Secretary
- Eugene ScavolaExecutive Vice President of Technical Operations
- Bradley J. CataloneHead of Drug Development
- Chris ChapmanChief Commercial Officer
Latest news about Verrica Pharmaceuticals
Key financials
Reported results for Verrica Pharmaceuticals, in USD.
- Market cap
- 55.1M
- Revenue (TTM)
- 30.3M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.7
- Dividend yield
- —
- Profit margin
- -102.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 35.6M | -11.9M | -17.9M | |
| 7.6M | -65.9M | -76.6M | |
| 5.1M | -65.8M | -67M | |
| 9M | -21.3M | -24.5M |